上海艾力斯医药科技股份有限公司2025 年半年度报告 公司代码：688578 公司简称：艾力斯 上海艾力斯医药科技股份有限公司 2025 年半年度报告 1 / 177 上海艾力斯医药科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述在经营过程中可能面临的各种风险因素，具体请查阅本报告"第 三节 管理层讨论与分析"之"四、风险因素"。 三、 公司全体董事出席董事会会议。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司 2025 年半年度利润分配方案为：拟以实施权益分派股权登记日登记的总股本为基数向全 体股东每 10 股派发现金红利 4.00 元（含税），截至 2025 年 6 月 30 日，公司总股本为 450,000,000 股，以此计算合计拟派发现金红利 180,000,000.00 元（含税）。本半年度不送红股，不进行资本 公积金转增股本。 七、 是否存在公司治理特殊安排等重要 ...

证券代码：688578 证券简称：艾力斯 公告编号：2025-017 上海艾力斯医药科技股份有限公司 第二届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海艾力斯医药科技股份有限公司（以下简称"公司"）第二届监事会第十 二次会议于 2025 年 8 月 25 日在公司会议室召开。本次会议由监事会主席张晓芳 女士召集并主持，应到监事 3 人，实到监事 3 人；本次会议的召集和召开程序符 合《中华人民共和国公司法》等法律法规、规范性文件以及《公司章程》的相关 规定，会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事审议，形成如下决议： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 监事会对公司 2025 年半年度报告及其摘要进行了审核，并发表审核意见如 下： （1）公司 2025 年半年度报告编制和审议程序符合法律法规、公司章程和公 司内部管理制度的各项规定； （2）公司 2025 年半年度报告公允反映了报告期内的财务状况和经营成果， 所 ...

证券代码：688578 证券简称：艾力斯 公告编号：2025-019 重要内容提示： 一、利润分配方案内容 2025 年 1-6 月，公司合并财务报表归属于上市公司股东的净利润为人民币 1,051,235,341.42 元，截至 2025 年 6 月 30 日，母公司报表期末未分配利润为人 民币 1,757,254,173.14 元。经董事会决议，公司 2025 年半年度拟以实施权益分派 股权登记日登记的总股本为基数分配利润。本次利润分配方案如下： 公司拟向全体股东每 10 股派发现金红利 4.00 元（含税）。截至 2025 年 6 月 30 日，公司总股本 450,000,000 股，以此计算合计拟派发现金红利 180,000,000.00 元（含税），现金分红金额占公司 2025 年半年度合并报表中归属于上市公司股东 的净利润的比例为 17.12%。本次不送红股，不进行资本公积金转增股本。 如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股/回 购股份/股权激励授予股份回购注销/重大资产重组股份回购注销等致使公司总股 本发生变动的，公司拟维持分配总额不变，相应调整每股分配比例。如后续总股 本 ...

艾力斯公告，2025年上半年营业收入23.74亿元，同比增长50.57%。净利润10.51亿元，同比增长 60.22%。拟以实施权益分派股权登记日登记的总股本为基数向全体股东每10股派发现金红利4元（含 税），合计拟派发现金红利1.8亿元（含税）。 ...

艾力斯 20250822 摘要 伏美替尼进入医保后销售额大幅增长，2023 年 Q1 至 Q2 环比增长显著， 体现了创新药的巨大潜力，销售费用率、研发和管理费用率均下降，规 模效应显现，2024 年净利率达 40%，预计 2025 年保持良好。 艾力斯围绕伏美替尼在 EGFR 突变领域深入布局，经典突变一二线适应 症已获批，辅助治疗预计 2026 年申请上市，20 号外显子和 PAX 突变 二线适应症已递交申请，一线适应症预计明年初完成三期临床并递交上 市申请。 伏美替尼安全性数据优于同类药物，可加量使用，公司探索与其他药物 联合用药，包括 PL1 小分子、MET ADC、FACT 抑制剂等，并与康宁杰 瑞合作开发双抗 ADC 药物，旨在提升疗效并拓展应用空间。 艾力斯积极引进和开发新的肺癌管线，如加克斯公司的 K84 和 SIX2 管 线梯队，与基石合作获得 RET 抑制剂 Platinum 销售权，K2G 产品 Gallacy 已获批用于 KRAS G12C 突变非小细胞肺癌二线治疗。 华亭产品已同时申报医保和商保目录，普拉替尼是首个完成地产化生产 的产品，成本控制具优势。公司布局与伏美替尼赛道契合的四 ...

Core Viewpoint - A significant block trade of 40,000 shares of Ailis occurred on August 20, with a transaction value of 2.8796 million yuan, reflecting a discount of 20.29% compared to the closing price of the day [1] Group 1: Block Trade Details - The block trade involved a transaction price of 71.99 yuan per share [1] - The buyer was Guohai Securities Co., Ltd. Sichuan Branch, while the seller was Changjiang Securities Co., Ltd. Wuhan Hanxi First Road Securities Branch [1] - In the last three months, Ailis has recorded a total of three block trades, amounting to 7.1361 million yuan [1] Group 2: Stock Performance - Ailis closed at 90.32 yuan on the day of the block trade, with a slight increase of 0.37% [1] - The daily turnover rate was 0.90%, with a total trading volume of 362 million yuan [1] - Over the past five days, the stock has seen a cumulative increase of 0.76%, with a net outflow of funds totaling 12.789 million yuan [1] Group 3: Margin Financing Data - The latest margin financing balance for Ailis is 834 million yuan, which has decreased by 20.7589 million yuan over the past five days, representing a decline of 2.43% [1]

Group 1 - A total of 8 stocks from the Sci-Tech Innovation Board (STAR Market) experienced block trading on August 20, with a cumulative transaction amount of 1.04 billion yuan and a total trading volume of 243.32 million shares [1][2] - The stock with the highest transaction amount was Changying Tong, with a trading volume of 1.22 million shares and a transaction amount of 60.34 million yuan. Other notable stocks included Canxin Technology and Funeng Technology, with transaction amounts of 19.01 million yuan and 8.48 million yuan, respectively [1][2] - All stocks involved in block trading were sold at a discount compared to their closing prices, with the highest discount rates seen in Ailis, Gaoling Information, and Borui Pharmaceutical, at 20.29%, 12.30%, and 9.09% respectively [1][2] Group 2 - In terms of capital flow, four stocks saw net inflows of funds, with Canxin Technology, Daotong Technology, and Borui Pharmaceutical leading with net inflows of 29.08 million yuan, 17.82 million yuan, and 5.44 million yuan, respectively. Conversely, Funeng Technology, Ailis, and Aiwei Technology experienced net outflows of 24.92 million yuan, 21.88 million yuan, and 3.79 million yuan [2] - The average increase for the stocks involved in block trading was 1.44%, with the highest increases recorded for Canxin Technology, Daotong Technology, and Changying Tong, at 7.59%, 1.86%, and 0.71% respectively [1][2]

Core Viewpoint - Shanghai Heyu Biopharmaceutical Technology Co., Ltd. announced the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, citric acid giredestrant, for treating KRAS G12C mutated non-small cell lung cancer (NSCLC) patients [1] Group 1 - The clinical study is an open-label Phase II trial assessing the safety, tolerability, and efficacy of ABSK043 combined with citric acid giredestrant in patients with locally advanced or metastatic NSCLC carrying KRAS G12C mutations [1] - The collaboration agreement between Heyu Biopharmaceutical and Ailis was established in March 2025 for the combined treatment of ABSK043 and citric acid giredestrant [1] - Previous disclosures indicated another collaboration exploring the combination of ABSK043 with Ailis's developed Vemurafenib for treating advanced NSCLC, with the first patient dosing expected to be completed by December 2024 [1] Group 2 - Updated Phase I study results show that ABSK043 as a monotherapy has demonstrated good safety and impressive anti-tumor activity, particularly in patients with high PD-L1 expression and those with EGFR or KRAS mutations [1]

Core Viewpoint - Shanghai Heyu Biopharmaceutical Technology Co., Ltd. announced the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, citric acid gorasetinib, for treating KRAS G12C mutated non-small cell lung cancer (NSCLC) patients [1] Group 1 - The IND application was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China [1] - The study is an open-label Phase II clinical trial assessing the safety, tolerability, and efficacy of ABSK043 in combination with citric acid gorasetinib for patients with locally advanced or metastatic NSCLC carrying KRAS G12C mutations [1] - A previous collaboration between Heyu and Elysium was disclosed to explore the combination of ABSK043 with Elysium's developed drug, furmetinib, for treating advanced NSCLC, with the first patient dosing expected to be completed by December 2024 [1] Group 2 - Updated Phase I study results show that ABSK043 as a monotherapy has good safety and impressive anti-tumor activity, with higher response rates observed in patients with high PD-L1 expression and those with EGFR or KRAS mutations [1]

Core Viewpoint - The approval of the IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor from Shanghai Elysium Pharmaceutical Technology Co., Ltd. marks a significant advancement in the treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC) patients [1] Group 1 - The IND application was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China [1] - The collaboration agreement between the company and Elysium regarding the combined use of ABSK043 and citric acid gorasetinib tablets was reached in March 2025 [1] - The study is an open-label Phase II clinical trial assessing the safety, tolerability, and efficacy of ABSK043 in combination with citric acid gorasetinib tablets for patients with locally advanced or metastatic NSCLC carrying the KRAS G12C mutation [1]